Botensilimab and balstilimab showed promising survival outcomes in advanced solid tumors, with a median OS of 17.2 months and 39% 24-month survival. The study reported a 17% overall response rate and ...
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in ...
Although desmoid tumors do not metastasize, they can be associated with recurrence rates of up to 77% after surgical ...
Merck officially opened its €150m filtration manufacturing facility at Blarney Business Park in Cork last month. The Blarney facility is part of Merck’s largest life science investment to date in ...
A rebound in global biotech deals this year looks set to accelerate as big pharmaceutical companies seek new sources of ...
SpringWorks Therapeutics Inc. shares SWTX were on track for a record percentage gain on Tuesday after the company got the first U.S. regulatory approval for a drug targeting a rare type of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback